Loading
Clusterin in Disease Pathology / Immune Cells in Cancer / Ferroptosis and Cancer Prognosis · Journal article
International Journal of Molecular Sciences · September 10, 2026
Raises a question worth testing. It does not answer one.
This is a narrative review synthesizing current understanding of ferroptosis as a mechanistic pathway in pediatric cancer biology and therapy. The source identifies ferroptosis induction as a potential therapeutic strategy in preclinical models of neuroblastoma, acute lymphoblastic leukemia, osteosarcoma, and medulloblastoma, but emphasizes that the role in pediatric cancer remains incompletely understood and that clinical translation faces significant challenges including tumor heterogeneity, drug delivery, and potential toxicity to developing tissues.
Journal article. Pediatric cancer patients (referenced indirectly through discussion of neuroblastoma, B-cell acute lymphoblastic leukemia, osteosarcoma, and medulloblastoma); studies reviewed are primarily preclinical models..
Ferroptosis is a regulated form of cell death caused by iron-dependent membrane lipid peroxidation, regulated by iron metabolism, lipid composition, metabolic pathways, and antioxidant systems. Targeting ferroptosis alone or in combination with chemotherapy, radiotherapy and immunotherapy has shown anticancer effects in preclinical models. Emerging evidence in neuroblastoma, B-cell acute lymphoblastic leukemia, osteosarcoma, and medulloblastoma supports involvement of ferroptosis-related pathways in tumor biology and treatment response.
Ferroptosis induction may represent a therapeutic strategy in selected pediatric cancer models, although tumor heterogeneity, drug delivery, and potential toxicity to developing tissues remain important translational challenges.
This review raises the hypothesis that ferroptosis pathways may be exploited therapeutically in pediatric cancers, but clinicians should recognize that no clinical trial data are presented, evidence remains preclinical, and substantial translational barriers—including drug delivery and safety in developing tissues—must be addressed before clinical application is feasible.
This is a narrative review summarizing preclinical mechanistic evidence and emerging concepts about ferroptosis in pediatric cancer, without reporting original clinical trial data, efficacy comparisons, or definitive human outcomes.
This review raises the hypothesis that ferroptosis pathways may be exploited therapeutically in pediatric cancers, but clinicians should recognize that no clinical trial data are presented, evidence remains preclinical, and substantial translational barriers—including drug delivery and safety in developing tissues—must be addressed before clinical application is feasible.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Ferroptosis is a regulated form of cell death caused by iron-dependent membrane lipid peroxidation. Iron metabolism, membrane lipid composition, cellular metabolic pathways, and antioxidant defense systems regulate ferroptosis. Recently, ferroptosis has attracted interest as a target in cancer therapy, in particular cancer cells have developed several biological adaptative mechanisms to evade ferroptosis, thus enhancing tumor progression, metastatic dissemination, stemness, and resistance to conventional therapies. Interestingly, ferroptosis is regulated by the tumor microenvironment, where hypoxia, immune cells, and stromal components can either stimulate or inhibit ferroptotic cell death. It has been demonstrated that targeting ferroptosis, alone or in combination with chemotherapy, radiotherapy and immunotherapy, has anticancer effects in preclinical models and may contribute to avoid treatment resistance. However, the role of ferroptosis in pediatric cancer remains incompletely understood since these kinds of tumors show different developmental, genomic, and metabolic features that may contribute to create different ferroptosis vulnerabilities. Emerging evidence in neuroblastoma, B-cell acute lymphoblastic leukemia, osteosarcoma, and medulloblastoma supports the involvement of ferroptosis-related pathways in tumor biology and treatment response. Preclinical studies also indicate that ferroptosis induction may represent a therapeutic strategy in selected pediatric cancer models, although tumor heterogeneity, drug delivery, and potential toxicity to developing tissues remain important translational challenges. This review summarizes the molecular mechanisms underlining the relationship between ferroptosis and cancer biology, tumor progression, tumor microenvironment, and therapy resistance, with particular interest in its emerging relevance and therapeutic potential in pediatric oncology, while critically considering the current evidence and major challenges for clinical translation.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.